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1.  Executive Summary 
   
Drug inhalation is quickly emerging in the field of drug delivery techniques, providing 
localized treatment for various types of lung disorders. To expand oral drug delivery, this project 
will focus on inhaled insulin therapy to provide a systemic treatment that will reduce the 
detrimental effects of diabetes. Previous research has shown that inhaled insulin is more efficient 
and preferable to patients compared to the commonly used insulin injection therapy. However, 
there are several problems associated with drug inhalation techniques, including the impaction of 
drug against the natural right angle geometry of the pharynx, which results in decreased 
deposition in the lungs. The goals of this project include the optimization of insulin drug particle 
diameter size, the optimization of particle density, and optimization of the peak inhalation rate of 
drug to reduce impaction against the pharynx and to maximize deposition in the lungs.   
Optimization of the aerosol insulin was done using a laminar flow COMSOL model. To 
simplify the model, a two dimensional, cross-section of the mouth and trachea was used as the 
biological system to measure the effectiveness of the delivery scheme. This model was used to 
test particles with density values ranging from 10 g/m3 to 800 g/m3, as well as particles with 
diameters ranging from 1 μm to 17.5 μm. In addition, particles were tested with peak inhalation 
rates ranging from 15 L/min to 90 L/min and inhaler insertion angles ranging from -10° to 10°. 
Using every permutation of particle density, particle diameter, peak inhalation rate, and insertion 
angle we sought to find the most optimal delivery system for deposition at the bottom of the 
trachea. Particle deposition was further analyzed by varying inhalation rate and particle 
parameters in a 2D turbulent flow model and a 3D laminar flow model.  
For the 2D laminar flow model, particle deposition was found to be the most sensitive to 
inhalation rate compared to the other experimental parameters. Results indicated that high 
inhalation rates (45-60 L/min), particles with low density (100-400 kg/m3) and low diameter (1-
7.5 μm) resulted in increased particle deposition, which agrees with literature. For the velocity 
profile we obtained, the peak normalized velocity values of 1.53 for the 15 L/min inhalation rate, 
1.37 for the 30 L/min inhalation rate, and 1.27 for the 90 L/min inhalation rate agree with the 
values recorded in literature. For the 2D turbulent flow model, varying inhalation rate, particle 
density and diameter appeared to have no significant effect on particle deposition. The turbulent 
model displayed particle depositions that were an order of magnitude lower than those of the 2D 
laminar model, which we believe to be due to turbulent dispersion effects. For the 3D laminar 
flow model, flow velocity did not vary in the z direction, which implies that the 2D laminar 
model is an appropriate representation of flow velocity 
Our model demonstrates the effects of changing various drug particle parameters on 
particle deposition. We recommend the use of particles with low density and low diameter along 
with high inhalation rates in order to reduce impaction in the oral cavity and increase deposition 
in the lungs. Since particle deposition was most sensitive to inhalation rate, when formulating 
oral drug treatment particles, the specific inhalation rate that is used should be carefully 
considered. 
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2.  Introduction 
  
2.1 Background 
 
Drug delivery via inhalation became a popular choice of respiratory care in the 20th 
century1. While it has been recently been a “hot” topic in the field of drug delivery, the use of 
inhalers actually dates back to the 18th century2. The popularity and interest surrounding this 
therapy has been partly due to the rise of diagnosed respiratory disorders, particularly that of 
asthma in the United States from 2001 to 20103. 
Another driving factor for the popularity of this treatment type included exploring 
noninvasive procedures to increase patient compliance. By varying treatment target, drug 
content, formulation and inhaler device design, researchers aim to deliver an optimal dose of 
drug content into systemic circulation via inhalation. 
Inhaled drug therapy has the potential to deliver high doses of drug treatment without any 
adverse systemic side effects3. Because the drug travels through the respiratory system and 
eventually becomes absorbed into the bloodstream, it avoids the highly acidic and digestive 
environment of the stomach3. Also, drug delivery via inhalation is especially attractive because 
the human lung endothelium is very permeable4. Thus, in addition to respiratory disorders, a 
variety of non-respiratory disorders and diseases have been targeted by inhaled drug delivery. 
Diabetes mellitus is a chronic disease characterized by high sugar levels in the blood that 
has been targeted by inhaled drug delivery. This disease affects 8.3% of the United States’ 
population and is caused by insulin deficiency, resistance to insulin, or both3. Type I diabetes is 
caused by an autoimmune deficiency in insulin production and requires daily insulin injections5. 
The more common case, Type II diabetes, is caused by a lack of insulin production or insulin 
resistance5. Physicians have found that tight control of blood glucose levels through insulin 
therapy reduces the detrimental effects of diabetes6. The most common form of treatment has 
been insulin injection therapy, but there are a few disadvantages associated with the therapy. 
First, the therapy has been shown to be absorbed too slowly into the bloodstream (serum peak of 
insulin at 60-150 min) compared to natural insulin secretion from the pancreas6. Additionally, 
patients can experience pain from frequent use of insulin injection needles. A majority of 
patients inject themselves too few times a day because of the inconveniences the therapy 
causes7.      
Inhaled insulin is an alternative method that is safe, efficient, and well tolerated by 
patients. One research group demonstrated that Type II-diabetic patients receiving Exubera 
inhaled insulin therapy showed lower rates of hyperglycemia (.2 less events per month) 
compared to patients receiving insulin injection therapy3. The same group showed that 15% more 
patients receiving the inhaled insulin therapy reached the American Diabetes Association goal of 
antibody binding (<7%)3. Another group that conducted multiple three-month human efficacy 
studies showed that inhaled insulin is rapidly absorbed into the bloodstream (serum peak at 5-60 
min)4. The same group showed that the inhaled insulin therapy was well tolerated, in that 92% of 
Type II diabetes patients requested for a one year extension of the therapy5. 
In general, while inhaled drug treatment is an attractive therapy option, there are several 
drawbacks associated with this type of therapy. A wide range and variation of inhaler device 
designs can lead to improper drug dosage, especially as improper inhaler technique is common 
among patients8. The main problem associated with inhaled drug delivery was low 
bioavailability for drug deposition1. In the early stages of the field, drug inhalation treatments 
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were only effectively delivery 10-15% of the nominal dose1. The decreased bioavailability can 
be attributed to inappropriate particle diameters that either result in particles becoming exhaled 
or unable to pass into the thoat1. Likewise, particle density then becomes an important factor that 
determines the deposition site of the particles1. 
Another determining factor for successful deposition into the lungs is inhaler velocity. If 
velocity is too high, particles become inertially impacted against the pharynx wall3. An optimal 
combination of these parameters will increase insulin particle deposition into the trachea, thus 
increasing bioavailability and effective therapeutic dosage. 
  
2.2 Design Objectives  
  
In this project, an accurate COMSOL computational model for insulin drug particles 
inhaled into the human oral cavity will be developed. Particle velocity and particle trajectories of 
these inhaled insulin drug particles will be analyzed. We aim to study how to minimize particle 
impaction against the pharynx, and thus maximize particle deposition into the trachea. Our 
computation model will be used to define the optimal combination of particle diameter, particle 
density, insertion angle and peak inhalation rate in order to maximum particle deposition. 
  
2.3 Terms Defined    
  
Particle Density: insulin drug particle density values that account for mass and volume 
characteristics  
Particle Diameter: insulin drug particle diameter values that describe particle size 
Inhalation Rate: volumetric flow rate of inhaled drug particles as they enter the oral cavity 
Initial Particle Velocity: initial velocity of the drug particles as they enter the oral cavity 
Insertion Angle: angle at which the “inhaler” is positioned is thus the angle at which particles 
enter the oral cavity with respect to the horizontal axis 
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2.4 Problem Schematic  
 
2.4.A 2D Model 
 
A 2D model was used to examine the fluid flow and particle tracing of the insulin drug 
particles for the implementation in COMSOL. A sagittal plane through the medial line of the oral 
cavity was used as the basis of our 2D model (Fig 1). It was assumed that the z-axis geometry 
was not required as the flow effects in that axis are minimal compared to the x- and y-axes. The 
model provided three representative areas that the particles could travel through, the air-filled 
central oral cavity and the two mucus filled layers at the top and bottom of the oral cavity. The 
mucus boundary layer was assumed to possess a constant thickness of 0.1mm9.  
 
Figure 1. Schematic of the human oral cavity that will be implemented in the model (Image adapted from [5]). The 
0.1mm thick mucus layer is marked in the schematic by the double-edged boundary9. Particles will enter the oral 
cavity via the inlet (diameter, d = 0.015m) labeled in green and exit at the outlet (diameter, d = 0.027m) labeled in 
red. Diameter values for the inlet and outlet were scaled from the scale provided5. 
   
 
The boundary layer of the oral cavity was modeled as a “stick” boundary with a 
probability, meaning that particles impacting any part of the oral cavity wall had a probability of 
sticking to the wall. For simplification purposes consistent with literature, a probability of 1 was 
used10. The model assumes uniform drug distribution at the mouth entrance prior to drug 
inhalation. In addition, the drug was assumed to all have uniform density and aerodynamic 
diameters for each treatment. The inhalation rate was implemented as a sinusoidal function to 
realistically model airflow during inhaled drug delivery. The particle tracing physics assumes 
that the main forces acting upon the particles are drag and gravitational forces. The fluid was 
assumed to be Newtonian and incompressible.  
The laminar models assumed laminar airflow throughout the geometry. Conversely, the 
turbulent model assumed turbulent airflow. The turbulent model employed the same oral cavity 
schematic, but with the absence of the two mucus layers. The two mucus layers were not 
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included due to the many complications that were introduced to the model from flow eddy 
formation that occurred at the mucus layers. 
The laminar flow model was selected due to a low Reynolds number, as the velocities of 
the fluid flow and fluid density were small values. Therefore, we assumed that the laminar model 
assumption was valid. However, we discovered that this was not true at the higher inhalation 
rates, and thus higher fluid velocities- this gave us motivation to test our model for turbulent 
flow. 
 
2.4.B 3D Model 
 
The same human oral cavity geometry used in the 2D laminar model was extruded 0.1m 
in the z-axis direction to produce a 3D oral cavity for laminar flow (Fig 2). The mucus layer 
boundary was not included in the 3D oral cavity walls.  
 
Figure 2. Schematic of the human oral cavity in 3D built by extruding the 2D schematic 0.1m in the z-direction. 
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3.  Results and Discussion 
  
3.1 2D Laminar Model 
 
3.1.A Velocity Profile  
 
Figure 3. 2D laminar velocity profiles for time range (0: 0.01: 0.5s) at the following time points: (A) t = 0.12s (B) t 
= 0.25s (C) t = 0.37s (D) t = 0.5s 
Velocity changed with time in the oral cavity (Fig 3). For the specified inlet inhalation 
rate of 30 L/min, air flow velocities increased with time to a maximum velocity of approximately 
5 m/s in the trachea at t = 0.25 s (Fig 3B). The narrow diameter of the pharynx and trachea is 
characteristic of a “bottle-neck” region and resulted in a high concentration of increased airflow 
velocity due to a reduced cross-sectional area. After the peak velocity at t = 0.25 s, air flow 
velocities decreased due to the sine-wave function specified at the inlet velocity (Fig 3C). 
Similarly to the 2D model, the 3D model also displayed a “bottle-neck” region resulting in a high 
concentration of higher velocities in the constricted area by the pharynx. For later time points (t 
= 0.5s), the middle region of the oral cavity demonstrated the effect of shear stresses on velocity 
(Fig 3D).  
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3.1.B Particle Tracing  
 
Figure 4. Particle trajectory plots in 2D laminar flow for time range (0: 0.01: 0.5s) at the time points: (A) t = 0.1s  
(B) t = 0.15s (C) t = 0.2s (D) t = 0.5s 
Particle trajectory paths changed with time (Fig 4). For initial time points (t = 0.1 s), 
particles entering the oral cavity closely followed the velocity profile of the inlet airflow, 
forming a ring of particles that moved forward as the airflow increased from the inlet (Fig 4A). 
The particles with highest velocity were found at the center region of the oral cavity where the 
maximum airflow was observed. Conversely, particles with the lowest velocities were in close 
proximity to the upper and bottom mucus layers and may have experienced shear forces. A short 
time period later (t = 0.15s), the plots indicated that particles traveling down the trachea 
possessed the greatest velocity (Fig 4B). Some particle velocities decreased as they continued 
their pathway down the trachea, particularly those near the mucus layers (Fig 4C). This 
demonstrates decreased particle velocity due to the effect of particle impact against the mucus 
layer and stick to the pharynx wall. At later time points (t=0.5s), most of the particles have 
settled or are traveling at relatively low velocities (Fig 4D).  
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3.1.C Particle Deposition  
 
Color intensity maps were constructed to display the results of particle fraction deposition 
due to varying parameters. Three sets of particle fraction deposition results are displayed (1) 
varying particle diameters, inhalation rates, and high particle density values (100 to 800 kg/m3) 
(Fig 5), (2) varying particle diameters, inhalation rates, and low particle density values (10 to 75 
kg/m3) (Fig 6) and (3) varying insertion angle, inhalation rates, and particle density values (10 to 
800 kg/m3) (Fig 7). Overall, the highest particle fraction deposition was 8.75% for a particle 
diameter of 7.5µm, particle density of 200 g/cm3, and inhalation rate of 60 L/min (Table B8).  
The laminar model was most sensitive to inhalation rate compared to the other 
experimental parameters of particle density, and particle diameter. This was true for both the 
high particle densities (Fig 5) and for low density cases (Fig 6). For low and high particle 
densities, fraction of particle deposition ranged from approximately 0 to 0.08.  
 
 
 
Figure 5. Color intensity map representing the 2D laminar flow deposition fraction of insulin particles as a function 
of particle diameter (µm), high particle density values (100-800 g/cm3), and inhalation rate (L/min). Map was 
constructed based on data from Tables B9-12. 
Higher flow rates (45 L/min, 60 L/min) generally have greater particle deposition as 
compared to the lower flow rates (15 L/min, 30 L/min) (Fig 5, 6). This was the case when 
inhalation rate and diameter were varied alongside the simulations for both low particle densities 
(Fig 6), and for high particle densities (Fig 5).  
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At low density values, there appears to be no significant particle deposition effect from 
varying particle density or diameter (Fig 6). At high density values, for lower inhalation rates, as 
particle diameter and density values are both increased, particle deposition increases (Fig 5). 
However, for higher inhalation rates, increases in particle diameter and densities resulted in 
decreased particle deposition (Fig 5).  
 
Figure 6. Color intensity map of deposition fraction of insulin particles as a function of particle diameter (µm), low 
particle density values (10-75 g/cm3), and inhalation rate (L/min). Map was constructed based on data from Tables 
5-8 
 
 
 
 
 
 
 
 
 
 
11 | P a g e  
 
When insertion angle, particle density and inhalation rate were varied, particle deposition 
appeared to still remain most sensitive to inhalation rate (Fig 7). As evidenced by the random 
array of colors, there was no notable consistent variation in the pattern of deposition with respect 
to the insertion angle parameter (Fig 7).  
 
 
Figure 7. Heat map of deposition fraction of insulin particles as a function of particle diameter (µm), particle density 
(g/cm3), and inhalation rate (L/min) based on data from Tables B13-16 
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3.2 2D Turbulent Model 
 
3.2.A Velocity Profile 
  
 
Figure 8. 2D Turbulent velocity profiles for time range (0:0.01:0.5s) at the following time points: (A) t = 0.12s (B) t 
= 0.25s (C) t = 0.47s (D) t = 0.5s 
The velocity profile pattern over time for the turbulent model is very similar to that of the 
laminar model. The velocity increases to a peak velocity of 12.3 m/s at 0.25 s (Fig 8B) and then 
decreases substantially after that. Velocities are consistently higher in the trachea compared to 
the oral cavity (Fig 8B, 8C). The narrow diameter of the trachea is characteristic of a “bottle-
neck” region and results in a significant increase in flow velocity (Fig 8A, 8B). A unique 
characteristic of the velocity profile in the Turbulent Model shown for the final time step (t = 0.5 
s) is the presence of a flow vortex in the oral cavity (Fig 8D).  
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3.2.B Particle Tracing 
 
 
Figure 9. Particle trajectory plots in 2D turbulent flow for time range (0:0.01:0.5) at the following time points: (A) t 
= 0.1s (B) t = 0.15s (C) t = 0.2s (D)t = 0.5s 
As with the laminar model, particle trajectories in the turbulent model change over time 
(Fig 9). However, particles progress through the cavity faster in the turbulent model. At the first 
time point (t = 0.1s), particles are just entering the oral cavity in the laminar model (Fig 9A), but 
there is already particle deposition in the turbulent model (Fig 9A). The velocity of particles 
tends to decrease as they continue their pathway down the trachea, which demonstrates the effect 
of particle impaction against the pharynx wall (Fig 9D). At the middle time points (t= 0.15 and 
0.2s), there appears to be particles in the upper region of the oral cavity moving circularly, which 
may indicate the presence of a flow vortex (Fig 9C, 9D).   
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3.2.C Particle Deposition 
Varying inhalation rate, particle diameter and density appeared to have no effect on 
particle deposition (Fig 10). While the laminar model showed a direct relationship between 
particle deposition and inhalation rate, for the Turbulent Model, the deposition for all inhalation 
rates is comparable. Additionally, the fraction of particles deposited in the turbulent model is 
about a magnitude smaller than that of the 2D laminar model (Fig 5). The fraction of particles 
deposited ranged from 0 to 0.02 for the turbulent model and 0.048 to 0.08 for the laminar model 
for the same densities tested (Fig 10, 5).  
 
Figure 10. Color intensity map of 2D turbulent flow deposition fraction of insulin particles as a function of particle 
diameter (µm), particle density (g/cm3), and inhalation rate (L/min) based on data from Tables B5-8, B13-16. 
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We believe that this decreased deposition occurred because of turbulent dispersion effects 
present in the oral cavity in the turbulent model. As indicated in (Fig 11) by the black circle, this 
flow vortex traps particles near the top boundary of the oral cavity. Particles trapped in this 
vortex move continuously along the vortex edges, where shear stress and air velocity are high, 
which negatively affects particle deposition at the bottom of the trachea12. 
 
 
Figure 11. Time = 0.5 seconds at 30 L/min 2D turbulent flow, particle diameter = 1µm, and particle density = 400 
g/cm3. This figure indicates how particles are be trapped in the vortex show in the black circle above. The flow 
vortex accounts for the low particle deposition for turbulent flow. 
Although the presence of a flow vortex in the turbulent model may explain low particle 
deposition, the absence of any correlation between the tested parameters of inhalation rate, 
particle density and diameter in relation to the extremely low particle fraction deposition should 
be interpreted with caution. It is possible that the COMSOL solver was solving within an error 
range due to the physics associated with the extreme complexity of turbulent flow, the number of 
particles entering the cavity being too small, or the particles being micro-sized.  
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3.3 3D Laminar Model 
 
3.3.A Velocity Profile 
 
 
Figure 12. Velocity Profiles for time range (0:0.01:0.5s) at the following time points: (A) t = 0.12s (B) t = 0.25s (C) 
t = 0.37s (D) t = 0.5s from five yz-planes. 
The velocity profile pattern over time in the 3D model was congruent with the previous 
2D model results. Velocity profiles were observed by taking five cross-sectional yz-planes (Fig 
12) and eight cross-sectional xz-planes (Fig 13) throughout the geometry for an inhalation rate of 
60 L/min. Air flow velocities increased with time to a maximum velocity observed at t = 0.25 s. 
After the peak velocity at t = 0.25 s, air flow velocities decreased due to the sine-wave function 
specified at the inlet velocity. Similarly to the 2D model, the 3D model also displayed a “bottle-
neck” region resulting in a high concentration of higher velocities in the constricted area by the 
pharynx. Velocities in the trachea were overall higher in the trachea due to the reduced area, 
which is consistent with our 2D model. Due to the consistent pattern of the airflow with the 2D 
model and small variation of velocities in the z-axis at the given time scales, the 2D model 
assumption may be accurate and appropriate for laminar flow. Most of the variation in the 
velocities in the z-direction occurs in the trachea at t = 0.25 s, with the center of the trachea 
having higher velocity airflow than the edges. 
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Figure 13. Velocity Profiles for time range (0,0.01,0.5s) at the following time points: (A) t=0.12s (B) t=0.25s (C) 
t=0.37s (D) t=0.5s from eight xz-planes. 
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3.3.B Particle Tracing  
 
Figure 14. 3D particle trajectory plots for time range (0:0.01:0.5s) at the following time points: (A) t = 0.07 s (B) t = 
0.14 s (C) t = 0.21 s (D) t = 0.50s.  
One thousand particles were specified at the inlet with uniform distribution with an 
inhalation rate of 60 L/min, particle diameter of 1 µm, and particle density of 200 kg/m3. The 
particle trajectory pattern in the 3D model agreed well with the particle trajectory pattern in the 
2D model. Particles entering the oral cavity at t = 0.07 s closely followed the airflow, forming a 
ring of particles that travelled outward as the airflow propelled forward from the inlet (Fig 14A). 
Particles with the highest velocities were found at the center of the oral cavity where the highest 
airflow velocities were also found. A short time later, higher velocities for the particles were 
observed in the trachea, which is consistent with the velocity profiles and the 2D model (Fig 
14B). Particles then deposited at the bottom of the trachea, as desired by the design objectives, 
with high velocities (Fig 14C). Other particles deposited at the oral cavity wall near the inlet in 
both the top and bottom layers with low velocities.  
3.3.C Particle Deposition 
 
The particle deposition pattern in the oral cavity walls was fairly uniform in the z-
direction (Fig 14D), while particles at the bottom of the trachea formed a circle of higher 
concentration of particles towards the center where the airflow was presumably higher from the 
xz-plane velocity plots. The total particle deposition at the bottom of the trachea, represented as 
the bottom outlet plane, was quantified to be 681 particles of the 1,000 particles at the inlet 
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(68.1%). The particle deposition rate in 3D laminar flow at the bottom of the trachea was larger 
than the corresponding particle deposition in the 2D laminar flow model by a factor of 8.  
The difference in the deposition rate in the 3D laminar model may be a result of a number 
of factors that are different from the 2D laminar model. First, the absence of the mucus layers of 
higher viscosity that slowed down particles in the 2D model may be a factor in the higher 
deposition rates. One thousand particles were used in the 3D model with a significantly larger 
volume in the geometry, compared to 10,000 particles in the 2D model for a facilitated 
computing process. Furthermore, a total of 5 particles (0.5%) deposited on the lateral boundaries 
layers of the geometry. The top and bottom layers of the oral cavity had a total of 84 particles 
deposit (8.4%). The larger volume in the oral cavity available for particle transport in the 3D 
laminar model reduces deposition on the oral cavity walls before the particles reach the bottom 
of the trachea as the laminar flow is fairly uniform and the highest velocities are concentrated 
towards the center of the airflow. A turbulent model may be more accurate in the 3D model for 
higher inhalation rates as it captures the effect of turbulence, such as vortex stretching, more 
fully than the 2D turbulent model does and may yield higher particle deposition rates in the oral 
cavity wall as a result [14]. 
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3.4 Accuracy Check 
 
3.4.A Laminar Velocity Profiles 
 
The velocity profile was obtained for a cutline designated from point (0.0651, 0.0746) to 
point (0.0786, 0.0925) by averaging the velocities over time for three different flow rates: 15 
L/min, 30 L/min, and 90 L/min. The velocities were then normalized by dividing by the initial 
inlet velocity value (Fig 15). The data was compared against experimental and computational 
fluid dynamic model results from a study by Heenan et al. (2003) (Fig 16) 6. The general trend of 
the curves is a sharp velocity increase from the left boundary, a relatively flat region towards the 
center, and a sharp decrease in velocity towards the right boundary is consistent with literature 
data (Fig 16) 6. Furthermore, the peak normalized velocity values of 1.53 for the 15 L/min flow 
rate, 1.37 for the 30 L/min flow rate, and 1.27 for 90 L/min agree with the experimental values 
recorded by Heenan et al (Fig 15)6. The normalized data values obtained from this model are 
more consistent with the experimental data than the CFD model from Heenan et al, especially for 
the lower flow rates.  
 
 
Figure 15. Velocity profile averaged over time for 15 L/min, 30 L/min, and 90 L/min for cutline from point (0.0651, 
0.0746) to point (0.0786, 0.0925). 
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Figure 16. Normalized velocity profile averaged over time (Imaged adapted from [6]).This figure shows congruence 
with our velocity profile averaged over time (Fig 15), showing that our model had a reasonable level of accuracy. 
 
3.4.B Laminar Deposition Results  
 
Bronsky et al. studied the effects of peak inspiratory aerolizer flow rates for the use of 
inhalers11.They had found that lower inspiratory rates (<30 L/min) not only prevented the 
aerosolization of particles, but decreased pre-aerosolized particle deposition into the lungs. 
Higher inspiratory rates (>60L/min) were found to increase aerosolization and deposition into the 
lungs.  
A study by Heyder demonstrated a consistent trend that particles with larger diameters 
reached the bottom of the trachea less effectively for particle diameter sizes in the range of 1-10 
µm, which was a pattern found in our results for the larger laminar inhalation rates13. In addition 
to particle diameter, the study also found that particles with greater density deposited onto to the 
oral cavity wall at higher rates without reaching the bottom of the trachea13. The particles with 
larger diameter and density showed increased deposition onto the oral cavity walls through 
impaction, which reduced the number of particles reaching the bottom of the trachea. 
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3.5 Sensitivity Analysis 
 
 
Figure 17. Sensitivity of particle deposition to turbulence in 2D flow. The figure shows that there is a very 
large difference between the deposition fractions for the two models. 
 
 
Figure 18. Sensitivity of particle deposition to laminar flow in 2D and 3D. The figure shows that there is a 
very large difference between the deposition fractions for the two models. 
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Sensitivity analysis was conducted by examining how using our 2D turbulent and 3D 
laminar would affect our particle deposition at the bottom of the trachea. For the analysis, we 
standardized the particle diameter at 1 µm, the particle density at 200 kg/m3, and the inhalation 
rate at 60 L/min. Looking at the 2D turbulent results in comparison to the 2D laminar results (Fig 
17), the deposition rates were smaller than our original 2D laminar model (1.3% in turbulent vs. 
8.4% in laminar). This is most likely caused by the trapped particles in the vortices found in the 
upper part of the oral cavity. These vortices are caused by the dispersion of kinetic energy based 
on the turbulent governing equations used. When comparing the 2D laminar results to the 3D 
laminar results (Fig 18), the deposition rates were significantly higher than the 2D laminar 
results (68% in 3D vs. 8.4% in laminar). By increasing the 2D model to 3D, you are increasing 
the free area for the particles from x2 to A*x3, while the particles to be trapped on the oral cavity 
surface from x to B*x2. We believe that the increased degree of freedom for movement in the 
oral cavity increased the particle deposition. 
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4.  Conclusion & Design Recommendations     
 
4.1 Conclusion 
 
The 2D laminar flow model demonstrated the direct relationship between inhalation rate 
and particle deposition in the tracheal region. The model was most sensitive to inhalation rate 
compared to the other experimental parameters. The laminar study indicated that at high 
inhalation rates (45-60 L/min), particles with low density (100-400 kg/m3) and low diameter (1-
7.5 micrometers) resulted in increased particle deposition. Even when the insertion angle of the 
inhaler was varied, the model still remained most sensitive to changes in inhalation rate. These 
results agree with literature, which shows that at high inhalation rates, particles with large 
diameters and densities are less likely to be deposited at the bottom of the trachea13.  
Varying inhalation rate, particle density and diameter appeared to have no significant 
effect on particle deposition for the 2D turbulent flow model. The 2D turbulent model displayed 
particle depositions that were an order of a magnitude lower than those of the 2D laminar model. 
This decreased deposition can be explained by turbulent dispersion effects present in the model, 
with particles becoming trapped in a flow vortex in the oral cavity. Nevertheless, the random 
pattern in particle deposition indicates that there are problems associated with our 
implementation in COMSOL associated with the increased complexity of turbulent flow.  
The velocity profiles and particle trajectories in the 3D laminar model qualitatively were 
in good agreement with the 2D laminar velocity profiles and particle trajectories. Velocity 
profiles and particle deposition patterns in the oral cavity were fairly uniform in the z-direction, 
indicating that a 2D laminar assumption may be accurate in this region. The center of the 
pharynx and trachea showed higher velocities and subsequent higher deposition of particles in 
the center of the bottom of the trachea.  
 
4.2 Implications & Relevance 
 
Our model demonstrates the importance of how the combinations of several factors have 
an effect on drug particle deposition. While inhalation rate was deemed to be the most sensitive 
parameter for particle deposition, there were slight differences in results when a range of particle 
diameters and densities were implemented. Thus, when formulating oral drug treatment particles, 
the various particle characteristics should be formulated with specific inhalation rates in mind. 
Using our model, it is possible to dictate whether a treatment involving oral inhalation drug 
delivery method can fit within the parameters required for optimal deposition. 
 
4.3 Design Recommendations 
 
Based on our 2D laminar study results, we determined that effective particle deposition 
was achieved at high inhalation rates (45-60 L/min), low density (100-400 kg/m^3) and low 
particle diameters (1-7.5 micrometers). Therefore, we would recommend designers of oral 
inhalers to focus on these three parameters: inlet velocity, particle diameter, and particle density. 
In terms of the model design, the turbulent model results indicated that the type of airflow 
selected had a significant effect on the particle deposition pattern. Changes in particle diameter, 
particle density, and inhalation rate parameters did not display a clear trend of effects on particle 
deposition at the bottom of the trachea for the turbulent model. Furthermore, while the general 
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pattern of airflow and particle trajectories were similar in the 3D to the 2D model, higher 
deposition rates were observed in the 3D model than the 2D laminar model. As a design 
recommendation, we suggest implementing the mucus layer to the 3D geometry to quantify the 
effects of the mucus layer on particle velocities and particle deposition at the bottom of the 
trachea. In addition, we recommend implementing turbulent flow in a 3D model for higher 
inhalation rates. Turbulent flow models are most realistic in 3D as the full extent of vortex 
stretching and other turbulent-flow characteristics can be implemented12. The turbulent airflow 
with subsequent turbulent dispersion of particles in 3D may yield a more realistic 
implementation of the relevant physics and help identify other parameters involved in the 
turbulent dispersion process.  
One of the main limitations associated with our model was the tracheal cut off boundary. 
For simplification purposes, the model of our oral cavity did not include the lower peripheral 
airways. Thus, it was assumed that particle deposition at the tracheal cut off boundary was 
equivalent to the particle deposition in the lungs. Thus, we recommend extending the model from 
the bottom of the trachea to include the bronchi and the lungs. A complete geometry of the 
respiratory system will allow for better quantification of bioavailable particle deposition directly 
on the surface of the lungs. Additionally, the 3D geometry was an extrusion of the 2D geometry 
in the z-direction. Ideally, we would recommend a more realistic geometry with smoother, more 
cylindrical outlines and overall shape. Furthermore, our model does not include biological 
variation to account for changes in the oral cavity based on factors such as gender and age.  
 
4.4 Realistic Constraints 
 
The constraints involved with implementing our model include cost, dosage flexibility, 
and safety. The average wholesale price of inhaled insulin is significantly higher (approximately 
$125) than that of insulin injection therapy14. Nevertheless, after analysis of customer 
requirements, the benefits associated with increased patient satisfaction with inhaled insulin may 
be deemed more important than the high cost. Additionally, any changes made to the insulin 
dosage, such as the rate at which particles are inhaled and particle size, need to be tested using 
clinical trials on numerous patients to ensure the dosage’s safety and effectiveness14. Lastly, 
although inhaled insulin is a promising alternative to injection therapy, it has some side effects 
that need to be examined further, including increased concentrations of insulin antibodies15. 
More research is needed to confirm the safety of inhalable insulin before it is fully utilized in a 
large scale.  
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APPENDIX A: Mathematical Model 
 
A1. Mesh 
 
2D Mesh 
 
An unstructured extremely fine mesh was applied to the schematic of the human oral 
cavity (Fig 2) to create a mesh structure consisting of 14,761 triangular elements for the laminar 
model (Fig 3). The mesh element size was calibrated for the general physics of the model; a 
higher density of elements were specified in regions with the highest velocity and particle 
trajectory changes, which included the inlet, pharynx, and trachea. The turbulent model featured 
a similar physics-based finer mesh with 19,337 elements (Fig 3).  
 
 
Figure A1. Unstructured extremely fine mesh for laminar model consisting of 14,761 triangular elements created for 
the oral cavity schematic. 
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Fig A2: Physics-controlled finer mesh consisting of 19,337 triangular elements created for the turbulent 
model. 
3D Mesh 
 
An unstructured finer mesh was applied to the schematic of the human oral cavity to 
create a mesh structure consisting of 29,796 tetrahedral elements (Fig 4).  
 
Figure A3. Unstructured finer mesh consisting of 29,796 tetrahedral elements created for the 3D oral cavity 
geometry. 
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A2. Governing Equations 
 
2D Laminar Model 
 
Oral drug delivery through inhalation was modeled as 2D laminar flow using the Navier-
Stokes equation for momentum conservation and the continuity equation for conservation of 
energy. Lagrangian particle tracing equations were used for tracking particle velocity and 
location. 
 
Continuity: 
 
Navier-Stokes: 
 
                              
Lagrangian Particle Tracing for Particle Velocity and Location: 
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2D Turbulent Model 
 
The momentum equation is a time-averaged equation of motion derived from the 2D 
Navier-Stokes equation for fluid flow. The Reynold’s number for our model at an inhalation rate 
of 60 L/min, a flow diameter of 0.015 m, and the dynamic viscosity and density of air was 
calculated to be 8,805. This low Reynold’s number justified our use of the k-ω turbulence model 
of laminar-to-turbulent two-phase flow, which includes the turbulent kinetic energy and pseudo-
vorticity equations1. The k-ω model solves for the rate at which the dissipation of turbulent 
kinetic energy occurs1.  
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3D Laminar Model 
 
The 3D model utilized the expanded the governing equations in the 2D laminar flow 
model to include thez-axis.  The governing equations used were the continuity equation, Navier-
Stokes, and Lagrangian particle tracing for particle velocity and location.  
 
Continuity in 3D: 
 
δρ
δt
+
δ(ρu)
δx
+
δ(ρv)
δy
+
δ(ρw)
δz
= 0 
Navier-Stokes in 3D: 
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A3. Boundary Conditions 
 
Flow Boundary Conditions 
 
• Oral cavity wall is rigid 
o The 2D Laminar model included a mucus layer with consistent thickness of 0.1 m 
throughout cavity wall9 
• No slip condition for fluid at the mucus boundary layer for the 2D laminar model 
• Pressure at inlet and outlet is 0 for 2D turbulent model 
• “Stick” condition  
• Average inhalation rate ranges from 15 L/min to 60L/min 
o Inhalation was based on a sine function 
 
Diffusion boundary Condition 
• Oral cavity wall is impermeable to drug flow 
 
 
A4. Assumptions 
 
Fluid Flow 
• Laminar airflow for the 2D & 3D laminar models and turbulent airflow for the 2D 
turbulent model 
• Incompressible and Newtonian fluid 
 
Particles 
• Particles acted upon by gravitational force, which was defined as a gravity vector (0, -9.81 
m/s2) 
• Particles upon by drag force defined by Stoke’s Law (predefined in COMSOL) 
• Particles are of uniform spherical sizes 
• For the turbulent model, particle deposition was not computed to the last time step due to 
computing limitations. For these parameter combinations, the particle deposition at the last 
computed time step was assumed to be the particle deposition.  
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A5. Input Parameters  
 
2D Laminar Input Parameters 
Table A1. Fluid properties for the various domains in the COMSOL model16 
Fluid Air Water 
Domain Oral cavity Mucous layer 
Density (g/m3) 1.225 1000 
Dynamic Viscosity (Pa*s) 1.181x10-5 8.9x10-4 
 
Table A2. Input parameters and variables. Parametric sweep analysis was completed by computing all 
combinations of particle density (g/m3), particle diameter (µm), and inhalation rate (m/s). The lower half 
of the table indicates the velocity parameters implemented into the model. The Laminar Flow module of 
the model uses an inhalation rate that is a function of time. Implementing inhalation rates into our 2D 
COMSOL model required that the volumetric flow rates (L/min) obtained from literature be converted a 
velocity rate (m/s). An approximation of the inlet oral cavity cross sectional area was used for this 
conversion. The inlet oral cavity was assumed to be a circle geometry, and the cross sectional area in the 
model was approximated as (𝜋𝑟2 = 𝜋 �0.015 𝑚
2
)2 = 1.77 ∗ 10−4𝑚2� 5. The Particle Tracing module of 
the model uses initial particle velocities that were calculated based on the assumption that inhalers are 
frequently used at an angle θ with respect to the horizontal2. 
# Particles17 10000 
Particle Density 
(g/m3) 17 
100 200 400 600 800 
Particle Diameter 
(µm) 17 
1 2.5 5 7.5 10 12.5 15 17.5 
Insertion Angle (θ)2 -10° -5° 0° 5° 10° 
 
(Laminar Flow Module) Inhalation Rate11 
Volumetric Flow Rate (L/min)  11 Velocity Rate, v (m/s)   Inhalation Rate = f(t)    
15  1.415  
v*sin (2π*t) 30  2.830  45 4.244 
60  5.659  
(Particle Tracing Module) Initial Particle Velocity (m/s)1 
ux 1.415 
uy 1.415*Sinθ 
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2D Turbulent Input Parameters 
Table A3: Input parameters and variables. Parametric sweep analysis was completed by computing all combinations 
of particle density (g/m3), particle diameter (µm), and inhalation rate (m/s). There were a few implementation 
differences in running the turbulent model compared to running the laminar model. Firstly, particle deposition was 
not examined at an inhalation rate of 15 L/min, as the model did not compute with this condition. This result can be 
explained by the turbulence intensity being very low12. At this low flow rate condition, inlet turbulence is 
diminished and laminar flow prevails12. Additionally, the number of particles entering the mouth was decreased 
from 10,000 to 1,000, as the turbulent model did not compute when the higher particle number was set. This 
discrepancy may have occurred due to the increased complexity associated with flow through the turbulent model.  
# Particles17 1000 
Particle Density 
(g/m3) 17 
100 200 400 600 800 
Particle 
Diameter (µm) 17 
1 2.5 5 7.5 10 12.5 15 17.5 
  
(Turbulent Flow Module) Inhalation Rate11 
Volumetric Flow Rate 
(L/min) 11 
Velocity Rate, v (m/s)  Inhalation Rate = f(t)  
30  2.830   
v*sin (2π*t) 45 4.244 
60  5.659  
(Particle Tracing Module) Initial Particle Velocity (m/s)1 
ux 1.415 
uy -0.249 
 
Two additional parameters specific for the turbulent model include the turbulence length scale, 
which was set to 1, and the turbulence intensity, which was set to 10% 12. 
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APPENDIX B: Solution Strategy  
 
B1. Mesh Convergence  
 
Velocity 
Mesh convergence was performed for laminar flow velocities at a cross section in the oral 
cavity at time t=0.25s. The cross section was defined from point (0.0651, 0.0746) to point 
(0.0786, 0.0925) (Fig 5). For meshes with a fewer number of elements, the velocity distribution 
across arc length curve was not that “smooth” (Fig 6). As the mesh was refined, the velocity 
distribution across arc length “smoothens” out and becomes less jagged (Fig 6). Eventually, the 
velocity distribution no longer changes with mesh refinement at approximately 16181 elements, 
and mesh convergence has been accomplished. It was also observed that the velocity of airflow 
was significantly decreased at the junction of oral cavity wall and mucosal layer (Fig 6). This 
was evidenced in sharp velocity reductions at the lower and upper arc length values (Fig 6).  
 
 
Figure B1. A) Cutline region designated from point (0.0651, 0.0746) to point (0.0786, 0.0925) for velocity profile    
B) Mesh convergence for laminar flow velocity profiles. 
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 Particle Trajectory 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B2. Particle trajectory plots for different mesh sizes at time = 0.13 sec for various maximum element size 
(ME).  (A) ME = 0.0427 m (B) ME = 0.00231 m (C) ME = 0.00115 m (D) ME = 0.00075 m (E) ME = 0.0005 m 
Mesh convergence was accomplished for particle trajectories. This is evidenced as the 
solution becomes independent of the mesh as the mesh becomes more refined. The changes in 
the solution between a complete mesh containing 14,797 and 16,181 number of elements become 
insignificant (Fig 7D, 7E). As number of mesh elements increases, and thus the mesh is refined, 
the solution becomes independent of the mesh discretization (Fig 7).  
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B2. Particle Deposition Data 
2D Laminar  
 
Table B1. 2D Laminar particle deposition at tracheal boundary for particle diameters and lower particle 
densities at an inhalation rate of 15 L/min. 
 
 
 
 
 
 
 
 
Table B2. 2D Laminar particle deposition at tracheal boundary for particle diameters and lower particle 
densities at an inhalation rate of 30 L/min. 
 
 
 
 
 
 
 
 
Table B3. 2D Laminar particle deposition at tracheal boundary for particle diameters and lower particle 
densities at an inhalation rate of 45 L/min. 
Inhalation rate = 15 
L/min 
Particle Density (g/cm3) 
10 25 50 75 
Particle 
Diameter 
(µm) 
1 0 544 545 541 
2.5 541 542 543 543 
5 543 540 543 545 
7.5 544 548 542 549 
10 547 543 544 543 
12.5 544 547 546 543 
15 551 545 549 544 
17.5 549 544 545 547 
Inhalation rate = 30 
L/min 
Particle Density (g/cm3) 
10 25 50 75 
Particle 
Diameter 
(µm) 
1 0 559 553 541 
2.5 554 550 564 555 
5 550 560 557 553 
7.5 550 559 555 563 
10 557 557 556 550 
12.5 547 551 565 551 
15 542 549 551 552 
17.5 557 551 565 566 
Inhalation rate = 45 
L/min 
Particle Density (g/cm3) 
10 25 50 75 
Particle 
Diameter 
(µm) 
1 0 661 663 672 
2.5 666 671 669 666 
5 672 667 668 657 
7.5 666 665 679 656 
10 662 674 655 657 
12.5 666 663 651 673 
15 670 674 675 673 
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Table B4. 2D Laminar particle deposition at tracheal boundary for particle diameters and lower particle 
densities at an inhalation rate of 60L/min 
 
 
 
 
 
 
 
Table B5. 2D Laminar particle fraction deposition at tracheal boundary for particle diameters and lower 
particle densities at an inhalation rate of 15 L/min. 
 
 
 
 
 
 
 
 
Table B6. 2D Laminar particle fraction deposition at tracheal boundary for particle diameters and lower 
particle densities at an inhalation rate of 30 L/min. 
17.5 657 661 676 687 
Inhalation rate = 60 
L/min 
Particle Density (g/cm3) 
10 25 50 75 
Particle 
Diameter 
(µm) 
1 0 767 765 756 
2.5 761 760 775 751 
5 749 766 753 763 
7.5 758 751 726 746 
10 761 726 779 740 
12.5 769 718 754 774 
15 767 769 761 767 
17.5 729 748 774 777 
Inhalation rate = 15 
L/min 
Particle Density (g/cm3) 
10 25 50 75 
Particle 
Diameter 
(µm) 
1 0 .0544 .0545 .0541 
2.5 .0541 .0542 .0543 .0543 
5 .0543 .054 .0543 .0545 
7.5 .0544 .0548 .0542 .0549 
10 .0547 .0543 .0544 .0543 
12.5 .0544 .0547 .0546 .0543 
15 .0551 .0545 .0549 .0544 
17.5 .0549 .0544 .0545 .0547 
Inhalation rate = 30 Particle Density (g/cm3) 
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Table B7. 2D Laminar particle fraction deposition at tracheal boundary for particle diameters and lower 
particle densities at an inhalation rate of 45 L/min. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table B8. 2D Laminar particle fraction deposition at tracheal boundary for particle diameters and lower 
particle densities at an inhalation rate of 60 L/min. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table B9. 2D Laminar particle fraction deposition at tracheal boundary for particle diameters and higher 
particle densities at an inhalation rate of 15 L/min. 
L/min 10 25 50 75 
Particle 
Diameter 
(µm) 
1 0 .0559 .0553 .0541 
2.5 .0554 .055 .0564 .0555 
5 .055 .056 .0557 .0553 
7.5 .055 .0559 .0555 .0563 
10 .0557 .0557 .0556 .055 
12.5 .0547 .0551 ..0565 .0551 
15 .0542 .0549 .0551 .0552 
17.5 .0557 .0.551 .0565 .0566 
Inhalation rate = 45 
L/min 
Particle Density (g/cm3) 
10 25 50 75 
Particle 
Diameter 
(µm) 
1 0 .0661 .0663 .0672 
2.5 .0666 .0671 .0669 .0666 
5 .0672 .0667 .0668 .0657 
7.5 .0666 .0665 .0679 .0656 
10 .0662 .0674 .0655 .0657 
12.5 .0666 .0663 .0651 .0673 
15 .0670 .0674 .0675 .0673 
17.5 .0657 .0661 .0676 .0687 
Inhalation rate = 60 
L/min 
Particle Density (g/cm3) 
10 25 50 75 
Particle 
Diameter 
(µm) 
1 0 .0767 .0765 .0756 
2.5 .0761 .0760 .0775 .0751 
5 .0749 .0766 .0753 .0763 
7.5 .0758 .0751 .0726 .0746 
10 .0761 .0726 .0779 .0740 
12.5 .0769 .0718 .0754 .0774 
15 .0767 .0769 .0761 .0767 
17.5 .0729 .0748 .0774 .0777 
Inhalation rate = 15 
L/min 
Particle Density (g/cm3) 
100 200 400 600 800 
Particle 1 0.0541 0.0538 0.0541 0.0542 0.0542 
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Table B10. 2D Laminar particle fraction deposition at tracheal boundary for particle diameters and higher 
particle densities at an inhalation rate of 30 L/min. 
 
Table B11. 2D Laminar particle fraction deposition at tracheal boundary for particle diameters and higher 
particle densities at an inhalation rate of 45 L/min. 
 
Table B12. 2D Laminar particle fraction deposition at tracheal boundary for particle diameters and higher 
particle densities at an inhalation rate of 60 L/min. 
 
Table B13. Particle deposition fractions for the varying insertion angle at an inhalation rate of 15 L/min. 
Diameter 
(µm) 
2.5 0.0544 0.0544 0.0544 0.0539 0.0538 
5 0.054 0.0539 0.0538 0.054 0.0541 
7.5 0.0546 0.0539 0.0545 0.0547 0.0535 
10 0.0539 0.0541 0.0544 0.0549 0.0553 
12.5 0.0543 0.055 0.0547 0.0542 0.0549 
Inhalation rate = 30 
L/min 
Particle Density (g/cm3) 
100 200 400 600 800 
Particle 
Diameter 
(µm) 
1 0.0491 0.0485 0.0486 0.0483 0.0483 
2.5 0.0481 0.0491 0.0491 0.0506 0.0505 
5 0.0498 0.0508 0.0512 0.0512 0.0525 
7.5 0.0495 0.0507 0.0537 0.0574 0.0578 
10 0.0508 0.052 0.0573 0.0611 0.0597 
12.5 0.0516 0.0567 0.0602 0.0605 0.058 
Inhalation rate = 45 
L/min 
Particle Density (g/cm3) 
100 200 400 600 800 
Particle 
Diameter 
(µm) 
1 0.0648 0.0641 0.0652 0.0651 0.064 
2.5 0.0639 0.0642 0.0656 0.0635 0.0612 
5 0.0649 0.0633 0.0641 0.0635 0.0631 
7.5 0.0626 0.0624 0.0637 0.0643 0.066 
10 0.063 0.0649 0.0653 0.0646 0.0677 
12.5 0.0647 0.0631 0.0657 0.0693 0.0692 
Inhalation rate = 45 
L/min 
Particle Density (g/cm3) 
100 200 400 600 800 
Particle 
Diameter 
(µm) 
1 0.0828 0.0841 0.0834 0.0853 0.0852 
2.5 0.086 0.0842 0.0854 0.0864 0.0866 
5 0.0862 0.0849 0.0846 0.0855 0.0872 
7.5 0.0837 0.0875 0.0859 0.0859 0.0843 
10 0.0863 0.0871 0.0857 0.0828 0.0789 
12.5 0.0843 0.0856 0.0826 0.0787 0.0752 
40 | P a g e  
 
Inhalation rate = 
15 L/min 
Particle Density (g/cm3) 
10 25 50 75 100 200 400 600 
Insertion 
Angle 
-10 0.0547 0.0546 0.0546 0.0546 0.0547 0.0542 0.0542 0.0551 
-5 0.0546 0.0545 0.055 0.0544 0.0545 0.0549 0.0548 0.0557 
0 0.0546 0.0547 0.0549 0.0546 0.0546 0.0544 0.0543 0.0555 
5 0.0545 0.0546 0.0549 0.0547 0.0547 0.0543 0.0541 0.0548 
10 0.0545 0.0546 0.0549 0.0547 0.0547 0.0543 0.0541 0.0548 
 
 
 
Table B14. Particle deposition fractions for the varying insertion angle at an inhalation rate of 30 L/min. 
Inhalation rate = 
30 L/min 
Particle Density (g/cm3) 
10 25 50 75 100 200 400 600 
Insertion 
Angle 
-10 0.0531 0.0521 0.0501 0.052 0.052 0.0529 0.0574 0.0591 
-5 0.053 0.0514 0.0519 0.0527 0.053 0.0528 0.0567 0.0587 
0 0.0527 0.0515 0.05 0.0496 0.0517 0.0519 0.0568 0.0584 
5 0.0537 0.052 0.0494 0.0474 0.0489 0.0508 0.0571 0.0587 
10 0.053 0.0513 0.0535 0.0503 0.0506 0.0512 0.0656 0.059 
 
Table B15. Particle deposition fractions for the varying insertion angle at an inhalation rate of 45 L/min. 
Inhalation rate = 
45 L/min 
Particle Density (g/cm3) 
10 25 50 75 100 200 400 600 
Insertion 
Angle 
-10 0.0613 0.0604 0.0618 0.0629 0.0632 0.0654 0.0675 0.0654 
-5 0.0623 0.0617 0.0631 0.0621 0.0624 0.0659 0.0676 0.0667 
0 0.062 0.0624 0.0614 0.0624 0.0628 0.0644 0.0686 0.0673 
5 0.0605 0.0633 0.0621 0.0624 0.0614 0.064 0.0676 0.0667 
10 0.0629 0.0619 0.0613 0.062 0.0633 0.0657 0.0662 0.0665 
 
Table B16. Particle deposition fractions for the varying insertion angle at an inhalation rate of 60 L/min. 
Inhalation rate = 
60 L/min 
Particle Density (g/cm3) 
10 25 50 75 100 200 400 600 
Insertion 
Angle 
-10 0.0782 0.0781 0.0798 0.0791 0.0787 0.0783 0.083 0.0788 
-5 0.0792 0.0792 0.0794 0.0785 0.08 0.0792 0.0813 0.0791 
0 0.0785 0.074 0.0779 0.078 0.0798 0.0779 0.0821 0.0785 
5 0.0786 0.0795 0.078 0.0791 0.0793 0.0778 0.0816 0.0792 
10 0.0783 0.0796 0.0787 0.0778 0.0806 0.0782 0.0831 0.0785 
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2D Turbulent 
Table B13. Particle deposition fractions for different particle densities and diameters at an inhalation rate 
of 30 L/min. 
Inhalation rate = 
30 L/min 
Particle Diameter (µm) 
1e-6 2.5e-6 5e-6 7.5e-6 10e-6 12.5e-
6 
15e-6 17.5e-
6 
 
Particle 
Density 
(g/cm3) 
100 .013 .008 .011 .013 .007 .01 .012 .015 
200 .009 0 .012 .009 .01 .014 .016 .013 
400 .014 .014 .01 .012 .014 .016 .015 .011 
600 .008 .012 .01 .01 .011 .008 .008 .001 
800 .015 .01 .011 .015 .015 .007 .005 .003 
 
 
Table B14. Particle deposition fractions for different particle densities and diameters at an inhalation rate 
of 45 L/min. 
Inhalation rate = 
45 L/min 
Particle Diameter (µm) 
1e-6 2.5e-6 5e-6 7.5e-6 10e-6 12.5e-
6 
15e-6 17.5e-
6 
 
Particle 
Density 
(g/cm3) 
100 .013 .016 0 0 .011 .014 .013 .011 
200 .013 .01 .014 .013 .014 .007 .013 .013 
400 .01 0  .011 .011 .013 .015 .013 .008 
600 .01 .007 .014 .013 .015 .014 .012 .004 
800 .01 .02 .016 .016 .015 .005 .006 .001 
 
Table B15. Particle deposition fractions for different particle densities and diameters at an inhalation rate 
of 60 L/min. 
Inhalation rate = 
60 L/min 
Particle Diameter (µm) 
1e-6 2.5e-6 5e-6 7.5e-6 10e-6 12.5e-
6 
15e-6 17.5e-
6 
 
Particle 
Density 
100 .011 .012 .013 .013 .014 .013 .013 .011 
200 .013 .011 .013 .012 .013 .009 .015 .011 
400 .009 .009 .01 .014 0 .009 .009 .01 
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(g/cm3) 600 .012 .01 .012 .009 .012 .01 .012 .009 
800 .002 .013 .013 .016 .002 .002 .013 .013 
 
 
 
 
 
 
APPENDIX C: Software Implementation 
 
C1.Solver 
 
 
Fig C1. Direct solver for laminar flow in COMSOL. 
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Fig C2. Iterative solver for particle tracing in COMSOL. 
Fig C3. Direct solver for 2D turbulent flow in COMSOL. 
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Fig C4. Iterative solver with maximum of 50 iterations for 3D laminar flow in COMSOL. 
 
Fig C5. Iterative solver for particle tracing in 3D laminar flow in COMSOL. 
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C2. COMSOL Specifications 
 
To run the 2D laminar flow model in COMSOL, the transient time stepping algorithm 
used was the “Laminar Flow” module. The time step used was 0.01 seconds and the relative 
tolerance was 0.8 (Fig C6A). Particle tracing was done in a separate solver using the “Particle 
Tracing for Fluid Flow” transient module with the same time step as that of the laminar flow 
module and a relative tolerance of 1.0E-5 (Fig C6C). The same specifications were used in the 
3D laminar flow model, except that a relative tolerance of 0.01 was used for the “Laminar Flow” 
module (Fig C6B) 
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Figure C6: Specifcations for the “Laminar Flow” module in (A) for the 2D laminar model and in (B) for 
the 3D laminar model. The “ParticleTracing for Fluid Flow” module on in (C) was run in a separate 
solver for both models 
 
Fig C7: Specifications for the “Turbulent Flow, k-ω” and the “ParticleTracing for Fluid Flow” modules 
run in the same solver.  
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To run the 2D turbulent flow model in COMSOL, the transient time stepping algorithm 
used was the “Turbulent Flow, k-ω” module. The time step used was 0.01 seconds and the 
relative tolerance was 0.5 (Fig C7). Particle tracing was done in the same solver using the 
“Particle Tracing for Fluid Flow” transient module.  
 
 
 
 
 
 
 
 
 
 
APPENDIX D: Additional visuals 
 
D1.Turbulent Velocity Profile 
 
 The velocity profile was obtained for a cutline designated from point (0.0651, 0.0746) to 
point (0.0786, 0.0925), just as for the laminar model, by averaging the velocities over time for 
three different flow rates: 30 L/min and 60 L/min. The velocities were then normalized by 
dividing by the initial inlet velocity value. The time-averaged velocity profiles for both flow 
rates are nearly identical (Fig 3).  
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Figure D1: Velocity profiles averaged over time for 30 L/min and 60 L/min for cutline from point 
(0.0651, 0.0746) to point (0.0786, 0.0925). 
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